Genmab (GMAB) Form 6-K details employee RSU and warrant grants

Rhea-AI Filing Summary

Genmab A/S filed a Form 6-K as a foreign private issuer for September 2025. The filing notes that a company announcement dated September 26, 2025 covers the grant of restricted stock units and warrants to employees of Genmab.

The Form 6-K is deemed incorporated by reference into several existing Genmab registration statements on Form S-8, meaning the information in this report becomes part of those employee equity compensation-related registrations from the filing date, unless later superseded by other filings.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF SEPTEMBER 2025

COMMISSION FILE NUMBER 001-38976

Genmab A/S
(Exact name of Registrant as specified in its charter)

Carl Jacobsens Vej 30

2500 Valby

Denmark

+45 70 20 27 28
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F 

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit			Description of Exhibit
99.1			Company Announcement Dated September 26, 2025: Grant of Restricted Stock Units and Warrants to Employees in Genmab

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			GENMAB A/S
			BY:			/s/ Anthony Pagano
						Name: Anthony Pagano
						Title: Executive Vice President & Chief Financial Officer

DATE: SEPTEMBER 26, 2025

FAQ

What does Genmab (GMAB) report in this September 2025 Form 6-K?

Genmab reports that a company announcement dated September 26, 2025 covers the grant of restricted stock units and warrants to employees. The Form 6-K mainly serves to furnish this announcement and link it into existing registration statements.

How is this Genmab (GMAB) Form 6-K linked to existing S-8 registrations?

The Form 6-K is deemed incorporated by reference into Genmab’s Form S-8 registration statements, identified by several file numbers. This means the information in this report becomes part of those employee share plan registrations from the filing date.

What corporate action is referenced in Genmab’s (GMAB) Exhibit 99.1?

Exhibit 99.1 is a company announcement dated September 26, 2025 describing the grant of restricted stock units and warrants to employees of Genmab. The Form 6-K itself mainly points to this announcement rather than detailing the grant terms.

Who signed the September 2025 Genmab (GMAB) Form 6-K?

The Form 6-K was signed on behalf of Genmab A/S by Anthony Pagano, who is identified as Executive Vice President and Chief Financial Officer. His signature indicates that he is duly authorized to sign the report for the company.

What type of issuer is Genmab (GMAB) in this Form 6-K filing?

Genmab files as a foreign private issuer using Form 6-K under Rules 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The filing also references Genmab’s use of Form 20-F for its annual reporting obligations.